Molecular Templates, Inc. Announces Change of Chief Financial Officer, Effective July 2, 2021
June 03, 2021 at 04:31 pm EDT
Share
On June 1, 2021, Adam Cutler, Chief Financial Officer, Treasurer and Secretary of Molecular Templates, Inc. informed the Company of his intent to resign from his positions to pursue another opportunity. Mr. Cutler’s last day of employment with the Company is expected to be on July 2, 2021. In connection with Mr. Cutler’s resignation, Sean McLennan, Senior Vice President, Finance and Controller, will serve as the Company’s principal financial officer and principal accounting officer on an interim basis upon Mr. Cutler’s departure. The Company has initiated a search for a new Chief Financial Officer.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Companyâs proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
MOLECULAR TEMPLATES, INC. 
